Idioma:

CAR T-cell therapy: Balance of efficacy and safety

Kulemzin, S. V. ; Kuznetsova, V. V. ; Mamonkin, M. ; Taranin, A. V. ; Gorchakov, A. A.

Molecular biology (New York), 2017-03, Vol.51 (2), p.237-250 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por

Título:
CAR T-cell therapy: Balance of efficacy and safety
Autor: Kulemzin, S. V. ; Kuznetsova, V. V. ; Mamonkin, M. ; Taranin, A. V. ; Gorchakov, A. A.
Assuntos: Animals ; Biochemistry ; Biomedical and Life Sciences ; Chimeric antigen receptors ; Hematologic Neoplasms - genetics ; Hematologic Neoplasms - immunology ; Hematologic Neoplasms - therapy ; Human Genetics ; Humans ; Immunotherapy - methods ; Life Sciences ; Lymphocytes T ; Oncogene Proteins, Fusion - genetics ; Oncogene Proteins, Fusion - immunology ; Receptors, Antigen, T-Cell - genetics ; Receptors, Antigen, T-Cell - immunology ; Reviews ; T-Lymphocytes - immunology ; T-Lymphocytes - transplantation
É parte de: Molecular biology (New York), 2017-03, Vol.51 (2), p.237-250
Descrição: Early results from clinical trials of autologous chimeric antigen receptor (CAR)-expressing T cells for the therapy of B-cell malignancies have encouraged extending the potency of this therapy to other cancers. However, the success of using CAR T-cells to treat patients with solid tumors has been limited. In this review, we summarize current knowledge on the design and applications of CARs for the targeted therapy of cancer. We describe existing issues that limit the widespread application of CAR T cells and discuss the optimization steps needed to further improve safety and efficacy of this therapeutic platform.
Editor: Moscow: Pleiades Publishing
Idioma: Inglês;Russo

Links

Voltar para lista de resultados